Related Experiment Video

Updated: Jun 19, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

C J Zappala1, P I Latsi, A G Nicholson

  • 1Royal Brompton Hospital and National Heart and Lung Institute, London, UK.

The European Respiratory Journal
|October 21, 2009
PubMed

Insights

Marginal declines in forced vital capacity (FVC) predict worse outcomes in idiopathic pulmonary fibrosis (IPF). These findings help identify patients with progressive disease for clinical trials and improve patient care.

Area of Science:

  • Pulmonary Medicine
  • Respiratory Research
  • Clinical Trials

Background:

  • Idiopathic pulmonary fibrosis (IPF) studies face challenges due to limited significant changes in pulmonary function tests (PFTs).
  • Evaluating the prognostic value of "marginal" PFT changes is crucial for understanding disease progression.

Purpose of the Study:

  • To assess the prognostic significance of marginal changes in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (D L,CO) in IPF and fibrotic non-specific interstitial pneumonia (NSIP).
  • To determine if marginal PFT changes can identify patients with more progressive disease for therapeutic studies.

Main Methods:

  • Retrospective analysis of biopsy-proven IPF (n=84) and NSIP (n=72) patients.
  • Categorization of 6-month FVC and D L,CO trends as "significant" or "marginal" based on predefined thresholds.
  • Proportional hazards analysis and time-dependent ROC methodology to correlate PFT trends with mortality and progression-free survival.

Main Results:

  • In IPF, both significant (26%) and marginal (23%) FVC declines were associated with higher mortality compared to stable disease.
  • Marginal FVC decline in IPF patients indicated lower progression-free survival.
  • Marginal changes in D L,CO in IPF and all marginal PFT changes in fibrotic NSIP did not yield significant prognostic information.

Conclusions:

  • Marginal decline in FVC in IPF is a significant indicator of poor prognosis.
  • These findings can inform clinical practice and patient selection for IPF therapeutic studies.
  • Focusing on marginal FVC changes aids in identifying IPF patients with more aggressive disease trajectories.

More Related Videos

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Related Concept Videos

Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...